Οξυκωδόνη 15mg

Oxycodone HCl 15mg – Mid-Range Opioid for Moderate-to-Severe Pain
(Available in Immediate-Release [IR] and Extended-Release [ER] Formulations)

Therapeutic Profile

• Ελεγχόμενη Ουσία Πίνακα II (High Abuse Potential)
• Onset/Duration:

• Υπέρυθρη ακτινοβολία: 15-30 min onset | 4-6 hr duration

• ER: 1-2 hr onset | 12 hr duration
  • Metabolism: Liver (CYP3A4/2D6) – Caution with inhibitors/inducers

Clinical Indications

✔ Breakthrough Cancer Pain (with ER baseline)
✔ Post-Surgical Pain (IR only, short-term)
✔ Chronic Pain (ER only for opioid-tolerant patients)
✔ Trauma/Injury Pain (IR, ≤5 day supply recommended)

Dosing Guidelines

For OPIOID-NAÏVE Patients (IR only):

• Not recommended as initial dose – start with 5mg

• Only after tolerance established: 15mg q4-6h PRN

For OPIOID-TOLERANT Patients:

• ER: 15mg q12h (must be on ≥30mg MEDD baseline)

• Υπέρυθρη ακτινοβολία: 15mg q4-6h PRN breakthrough pain

Σημαντικές Σημειώσεις Διαχείρισης:

• ER Tablets: Must swallow whole – never crush/chew (risk of fatal overdose)

• IR Tablets: May be split for dose titration

• Food Effect: High-fat meals increase ER absorption

Abuse-Deterrent Formulations

• OxyContin ER 15mg: Round, gray tablet with “OP” on one side

• Xtampza ER: Capsule formulation (tamper-resistant)

• IR Options: Oxaydo (nasal abuse-resistant)

Black Box Warnings

⚠️ HIGH ADDICTION/OVERDOSE RISK
⚠️ LIFE-THREATENING RESPIRATORY DEPRESSION (especially with alcohol/benzos)
⚠️ NEONATAL OPIOID WITHDRAWAL SYNDROME

Safety & Monitoring Requirements

• Naloxone Co-Prescription Mandatory
• PDMP Check Before Each Prescription
• Urine Drug Screening for Chronic Use
• Αποθήκευση: Locked container required
• Max Initial IR Prescription: 3-7 day supply

Special Populations

• Elderly: Reduce dose by 25-50%

• Νεφρική δυσλειτουργία: Avoid ER if CrCl <30mL/min

• Hepatic Dysfunction: Start with 50% dose